* 71 participants were recruited, among which 19 did not meet inclusion criteria

** An additional 410 participants were excluded from the analysis considering the cohort of 2009 participants

*** Age (mean and standard deviation) distributions were reported for the low-dose and high-dose groups separately

**** A, 1y and 2y were reported if possible but not mandatory

STUDY DESIGN


intravenous


oral


intramuscular


cross-over design


prospective


retrospective

PARTICIPANTS

NR: not reported

D: information available to evaluate the distribution

A: participants recruited in acute phase after SCI

C: participants recruited in chronic phase after SCI

ASSESSMENT INFORMATION

1/3/4/5/6/7/<8d: 1/3/4/5/6/7/<8 days after injury

3/4/6/12/26/52w: 3/4/6/12/26/52 weeks after injury

1-3/3-6/6/6-12/12m: 1-3/3-6/6/6-12/12 months after injury

1y: 1 year

A: acute

D: discharge

A(H): acute (hospital)

A(R): acute (rehabilitation)

D(R): discharge (rehabilitation)

DRUG EFFECT


positive effect reported


no effect reported


mixed effects reported
(nature of difference stated below)